High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer

Abstract

Oral fungal infections frequently develop in individuals with advanced cancer. This study examined the oral mycological flora of 207 patients receiving palliative care for advanced malignant disease. Demographic details and a clinical history were documented from each participant. A tongue swab was collected and cultured on CHROMAgar Candida^® (CHROMAgar Paris, France). All yeasts were identified by germ tube test, API ID 32C profiles and, for Candida dubliniensis, by species-specific PCR. Susceptibility to fluconazole and itraconazole was determined by a broth microdilution assay according to the National Committee for Clinical Laboratory Standards (NCCLS). At time of sampling, 54 (26%) of the 207 subjects had clinical evidence of a fungal infection and yeasts were isolated from 139 (67%) individuals. In total, 194 yeasts were isolated, of which 95 (49%) were Candida albicans. There was a high prevalence of Candidia glabrata (47 isolates) of which 34 (72%) were resistant to both fluconazole and itraconazole. All nine isolates of C. dubliniensis recovered were susceptible to both azoles. No relationship was established between anti-fungal usage in the preceding three months and the presence of azole resistant yeasts. This study of patients with advanced cancer has demonstrated a high incidence of oral colonization with non-C. albicans yeasts, many of which had reduced susceptibility to fluconazole and itraconazole. The role of improved oral care regimes and novel anti-fungal drugs merits further attention, to reduce the occurrence of fungal infection in these patients.

Keywords

azole anti-fungals Candida spp oral health palliative care

Get full access to this article

View all access options for this article.

References

Aldred MJ , Addy M , Bagg J , Finlay I . Oral health in the terminally ill: a cross-sectional pilot survey. Spec Care Dentist 1991; 11: 59–62.

Clarke JGM , Wilson J , Von Haacke NP , Milne LJR . Oral candidiasis in terminal illness. Health Bull (Edinb) 1987; 45: 268–271.

Finlay IG . Oral symptoms and candida in the terminally ill. Br Med J 1986; 292: 592–593.

Pople J , Oliver D . Oral thrush in hospice patients. Nurs Times 1986; 82: 34–35.

Jobbins J , Bagg J , Addy M , Newcombe RG , Finlay IG . Oral and dental disease in terminally ill cancer patients. Br Med J 1992; 304: 1612-1612.

Sweeney MP , Bagg J , Baxter WP , Aitchison TC . Oral disease in terminally ill patients with xerostomia. Oral Oncol (Eur J Cancer, Part B) 1998; 34: 123–126.

Johnson EM , Warnock DW , Luker J , Porter SR , Scully C . Emergence of azole drug resistance in Candida species from HIV-infected species receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35: 103–114.

Lopez J , Pernot C , Aho S , et al. Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J Hosp Infect 2001; 48: 122–128.

Sobel JD , Ohmit SE , Schuman P , et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001; 183: 286–293.

10.

Arias A , Arevalo MP , Andreu A , Rodriguez C , Sierra A . Candida glabrata: in vitro susceptibility of 84 isolates to eight anti-fungal agents. Chemotherapy 1996; 42: 107–111.

11.

Berrouane YF , Hollis RJ , Pfaller MA . Strain variation among and anti-fungal susceptibilities of isolates of Candida krusei. J Clin Microbiol 1996; 34: 1856–1858.

12.

Sullivan DJ , Westerneng TJ , Haynes KA , Bennett DE , Coleman DC . Candida dubliniensis sp. nov.: phenotypic and molecular characterisation of a novel species associated with oral candidosis in HIV-infected individua ls. Microbiology 1995; 141: 1507–1521.

13.

Coleman DC , Sullivan DJ , Bennett DE , Moran GP , Barry HJ , Shanley DB . Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 1997; 11: 557–567.

14.

Jobbins J , Bagg J , Parsons K , Finlay I , Addy M , Newcombe RG . Oral carriage of yeasts, coliforms and staphylococci in patients with advanced malignant disease. J Oral Pathol Med 1992; 21: 305–308.

15.

Davies AN , Brailsford S , Broadley K , Beighton D . Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 2002; 17: 79–84.

16.

Davies A , Brailsford S , Broadley K , Beighton D . Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliat Med 2002; 16: 527–531.

17.

Sullivan D , Coleman D . Candida dubliniensis: characteristics and identification. J Clin Microbiol 1998; 36: 329–334.

18.

Donnelly SM , Sullivan DJ , Shanley DB , Coleman DC . Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 1999; 145: 1871–1882.

19.

NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. 1997, M27A Vol 17, No 9.

20.

Fidel PL , Vazquez JA , Sobel JD . Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80–96.

21.

Moran GP , Sanglard D , Donnelly SM , Shanley DB , Sullivan DJ , Coleman DC . Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 1998; 42: 1819–1830.

22.

White TC , Marr KA , Bowden RA . Clinical, cellular and molecular factors that contribute to anti-fungal drug resistance. Clin Microbiol Rev 1998; 11: 382–402.

23.

Maenza JR , Merz WG , Romagnoli MJ , Keruly JC , Moore RD , Gallant JE . Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24: 28–34.

24.

Rubin AI , Bagheri B , Scher RK . Six novel antimycotics. Am J Clin Dermatol 2002; 3: 71–81.